Reduction of different inflammatory cell types of the innate immune system in psoriatic skin during etanercept treatment

被引：7

作者：

de Groot, Marjan ^{[1
]}

Teunissen, Marcel B. M. ^{[1
]}

Picavet, Daisy I. ^{[1
]}

de Rie, Menno A. ^{[1
]}

Bos, Jan D. ^{[1
]}

机构：

[1] Univ Amsterdam, Acad Med Ctr, Dept Dermatol, NL-1100 DE Amsterdam, Netherlands

来源：

EXPERIMENTAL DERMATOLOGY | 2010年 / 19卷 / 08期

关键词：

etanercept; psoriasis; innate immunity; skin inflammation; INFLIXIMAB THERAPY; TNF-ALPHA; ANTIMICROBIAL PROTEINS; CLINICAL-RESPONSE; DENDRITIC CELLS; DOUBLE-BLIND; T-CELLS; KERATINOCYTES; ACTIVATION; EXPRESSION;

D O I：

10.1111/j.1600-0625.2010.01089.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100227 [皮肤病学];

摘要：

To investigate whether specific markers for innate immunity would diminish with successful treatment in psoriasis, we analyzed lesional and non-lesional skin biopsies taken from patients with moderate to severe psoriasis during 12 weeks of treatment with etanercept in correlation with the clinical response. In the clinical responders (PASI reduction > 50%), all markers (CD3, CD68, CD161, elastase, BDCA-2, TNF-alpha) showed a decline during treatment, indicating a pivotal role for innate immunity in the pathogenesis of psoriasis.

引用

页码：754 / 756

页数：3

共 31 条

[1]

Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells [J].

Abrams, JR ;

Kelley, SL ;

Hayes, E ;

Kikuchi, T ;

Brown, MJ ;

Kang, SW ;

Lebwohl, MG ;

Guzzo, CA ;

Jegasothy, BV ;

Linsley, PS ;

Krueger, JG .

JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (05) :681-693

[2]

Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis [J].

Baker, BS ;

Ovigne, JM ;

Powles, AV ;

Corcoran, S ;

Fry, L .

BRITISH JOURNAL OF DERMATOLOGY, 2003, 148 (04) :670-679

[3]

Psoriasis, innate immunity, and gene pools [J].

Bos, Jan D. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (03) :468-471

[4]

Psoriasis: dysregulation of innate immunity [J].

Bos, JD ;

de Rie, MA ;

Teunissen, MBM ;

Piskin, G .

BRITISH JOURNAL OF DERMATOLOGY, 2005, 152 (06) :1098-1107

[5]

Bovenschen HJ, 2005, EUR J DERMATOL, V15, P454

[6]

High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis [J].

de Jongh, GJ ;

Zeeuwen, PLJM ;

Kucharekova, M ;

Pfundt, R ;

van der Valk, PG ;

Blokx, W ;

Dogan, A ;

Hiemstra, PS ;

van de Kerkhof, PC ;

Schalkwijk, J .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 125 (06) :1163-1173

[7]

GEARING A J H, 1990, Cytokine, V2, P68, DOI 10.1016/1043-4666(90)90045-U

[8]

Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study [J].

Goedkoop, AY ;

Kraan, MC ;

Picavet, DI ;

de Rie, MA ;

Teunissen, MBM ;

Bos, JD ;

Tak, PP .

ARTHRITIS RESEARCH & THERAPY, 2004, 6 (04) :R326-R334

[9]

Early effects of tumour necrosis factor α blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis [J].

Goedkoop, AY ;

Kraan, MC ;

Teunissen, MBM ;

Picavet, DI ;

de Rie, MA ;

Bos, JD ;

Tak, PP .

ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (07) :769-773

[10]

Clinical response to alimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study [J].

Gordon, Kenneth B. ;

Langley, Richard G. ;

Leonardi, Craig ;

Toth, Darryl ;

Menter, M. Alan ;

Kang, Sewon ;

Heffernan, Michael ;

Miller, Bruce ;

Hamlin, Regina ;

Lim, Liberata ;

Zhong, Jianhua ;

Hoffman, Rebecca ;

Okun, Martin M. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 55 (04) :598-606

← 1 2 3 4 →